Peptide therapy claims on TikTok: what the science says

What did @kristisawicki actually say?

She pushed back on commenters who claimed her 10 mg epithalon dosing figure came from studies on epithalamine, a pineal gland extract, rather than synthetic epithalon (the tetrapeptide Ala-Glu-Asp-Gly). Her core point: she sourced the figure from published literature and has not found a peer-reviewed paper that clearly separates the two compounds and specifically supports the lower microgram dosing that commenters cited. She asked viewers to share actual references. That is a reasonable, honest ask.

She also acknowledged the complicating factors plainly: the primary research is old, published in Russian, and potentially subject to translation errors. She did not oversell epithalon, did not claim it treats any disease, and did not push a specific protocol. For a peptide TikTok, that level of epistemic honesty is rarer than it should be.

Does the science back this up?

Partially, yes. The distinction between epithalamine and synthetic epithalon is real and scientifically meaningful, but the published record on dosing is genuinely murky. Commenters raising this point are not wrong to flag it, but they also may not have the receipts they think they do.

Epithalamine is a crude polypeptide extract from bovine pineal glands, studied extensively by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology starting in the 1970s and 80s. Epithalon (also spelled epitalon) is the isolated synthetic tetrapeptide derived from that work. Khavinson et al. published on both, sometimes in the same research arc, and the dosing contexts differ. However, a clean, English-language, peer-reviewed paper that explicitly states synthetic epithalon requires only microgram-range dosing compared to the milligram doses used in epithalamine studies is not easy to locate. A 2003 paper by Khavinson in Neuroendocrinology Letters describes synthetic epithalon administration in human trials, but dosing clarity across translated sources remains inconsistent.

What did they get wrong (or right)?

Kristi got the core problem right. The epithalon literature is a translation and conflation minefield. Khavinson's group published prolifically, but much of the foundational work appeared in Russian journals like Bulletin of Experimental Biology and Medicine, and translation quality varies. The concern that a 10 mg figure might carry over from epithalamine studies rather than synthetic epithalon studies is a legitimate methodological question, not a nitpick.

Where things get complicated is that even within Khavinson's synthetic epithalon human studies, the dosing reported is not always consistent, and study designs varied considerably. Some animal studies used doses that do not translate linearly to human equivalents. Commenters citing "microgram dosing" as settled science are also on shaky ground. Neither side of this debate has a definitive, replicable, modern clinical trial to point to. That is the honest answer, and she essentially said as much. Credit where it is due.

What should you actually know?

Epithalon has not been tested in large-scale, randomized, controlled human trials by Western regulatory standards. The existing human data comes almost entirely from one research group in Russia over several decades. That does not automatically invalidate the research, but it does mean the dosing figures circulating in peptide communities, whether milligrams or micrograms, are not grounded in the kind of evidence that would satisfy an FDA review.

The epithalamine versus epithalon distinction matters clinically because an extract and a synthetic tetrapeptide are not the same compound and should not be assumed to share identical pharmacokinetics or effective dose ranges. Anyone citing one body of research to justify dosing the other is making an inferential leap the data does not fully support. Until adequately powered, independent replication studies exist, all dosing discussions for synthetic epithalon are, at best, informed speculation. Kristi's instinct to track down primary sources before repeating a claim is exactly the right approach.